Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ed Silverman

Showing results (1-10 of 65) with videos related to

Pageof 7
Sort By:
Biotechnology Healthcare|April 6, 2012
Setting the Bar Higher For Off-Label Use of Biologics: Off-label use of biologics is common as physicians strive for optimal treatment. Patients want whatever works. Drug makers want expanded labeling, but payers chafe at the lack of efficacy data. Is there an answer to this conundrum?Ed Silverman
Biotechnology Healthcare|April 6, 2012
Creating a pathway over the regulatory chasm: a fresh startEd Silverman
Managed Care (Langhorne, Pa.)|June 15, 2011
FDA approvals of old drugs put new pressure on payersEd Silverman
Managed Care (Langhorne, Pa.)|June 13, 2019
Once-a-day HIV Treatment: Pricey But Perhaps Worth ItEd Silverman
Managed Care (Langhorne, Pa.)|January 26, 2017
Plans Favor Product Preferencing To Tame Spending on BiologicsEd Silverman
Biotechnology Healthcare|October 24, 2012
Showdown in steel cityEd Silverman
Biotechnology Healthcare|February 21, 2013
The first generation of biodrug management: to what results?Ed Silverman
Biotechnology Healthcare|January 16, 2013
Business savvy in the age of biologicsEd Silverman
BMJ (Clinical Research Ed.)|June 14, 2013
Pfizer versus Kaiser: insurers want their day in courtEd Silverman
Social Work|July 10, 2008
From ideological to competency-based: the rebranding and maintaining of medical social work's identityEd Silverman
Pageof 7

Showing results (1-10 of 65) with videos related to

Sort By:
Pageof 7
Biotechnology Healthcare|April 6, 2012
Setting the Bar Higher For Off-Label Use of Biologics: Off-label use of biologics is common as physicians strive for optimal treatment. Patients want whatever works. Drug makers want expanded labeling, but payers chafe at the lack of efficacy data. Is there an answer to this conundrum?Ed Silverman
Biotechnology Healthcare|April 6, 2012
Creating a pathway over the regulatory chasm: a fresh startEd Silverman
Managed Care (Langhorne, Pa.)|June 15, 2011
FDA approvals of old drugs put new pressure on payersEd Silverman
Managed Care (Langhorne, Pa.)|June 13, 2019
Once-a-day HIV Treatment: Pricey But Perhaps Worth ItEd Silverman
Managed Care (Langhorne, Pa.)|January 26, 2017
Plans Favor Product Preferencing To Tame Spending on BiologicsEd Silverman
Biotechnology Healthcare|October 24, 2012
Showdown in steel cityEd Silverman
Biotechnology Healthcare|February 21, 2013
The first generation of biodrug management: to what results?Ed Silverman
Biotechnology Healthcare|January 16, 2013
Business savvy in the age of biologicsEd Silverman
BMJ (Clinical Research Ed.)|June 14, 2013
Pfizer versus Kaiser: insurers want their day in courtEd Silverman
Social Work|July 10, 2008
From ideological to competency-based: the rebranding and maintaining of medical social work's identityEd Silverman
Pageof 7